NCT04483778

Brief Summary

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a B7H3-specific receptor (chimeric antigen receptor, or CAR) that will target and kill solid tumors that express B7H3. On Arm A of the study, research participants will receive B7H3-specific CAR T cells only. On Arm B of the study, research participants will receive CAR T cells directed at B7H3 and CD19, a marker on the surface of B lymphocytes, following the hypothesis that CD19+ B cells serving in their normal role as antigen presenting cells to T cells will promote the expansion and persistence of the CAR T cells. Arm A CAR T cells include the protein EGFRt and Arm B CAR T cells include the protein HER2tG. These proteins can be used to both track and destroy the CAR T cells in case of undue toxicity. The primary objectives of the study will be to determine the feasibility of manufacturing the cell products, the safety of the T cell product infusion, to determine the maximum tolerated dose of the CAR T cells products, to describe the full toxicity profile of each product, and determine the persistence of the modified cell in the participant's body on each arm. Participants will receive a single dose of T cells comprised of two different subtypes of T cells (CD4 and CD8 T cells) felt to benefit one another once administered to the research participants for improved potential therapeutic effect. The secondary objectives of this protocol are to study the number of modified cells in the patients and the duration they continue to be at detectable levels. The investigators will also quantitate anti-tumor efficacy on each arm. Participants who experience significant and potentially life-threatening toxicities (other than clinically manageable toxicities related to T cells working, called cytokine release syndrome) will receive infusions of cetuximab (an antibody commercially available that targets EGFRt) or trastuzumab (an antibody commercially available that targets HER2tG) to assess the ability of the EGFRt on the T cells to be an effective suicide mechanism for the elimination of the transferred T cell products.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P75+ for phase_1

Timeline
177mo left

Started Jul 2020

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Jul 2020Dec 2040

Study Start

First participant enrolled

July 13, 2020

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

July 14, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 23, 2020

Completed
20.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2040

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2040

Last Updated

April 28, 2026

Status Verified

November 1, 2025

Enrollment Period

20.4 years

First QC Date

July 14, 2020

Last Update Submit

April 23, 2026

Conditions

Keywords

CAR T cellPediatricYoung adultsNon-CNS solid tumor

Outcome Measures

Primary Outcomes (9)

  • Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express B7H3-specific CAR (Arm A)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • Assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a bispecific B7H3xCD19 CAR (Arm B)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • To assess the safety and tolerability of cellular immunotherapy utilizing ex-vivo expanded autologous T cells genetically modified to express a bispecific B7H3xCD19 CAR given in combination with pembrolizumab (Arm C)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized to determine maximal tolerated dose

    28 days

  • To determine the maximum tolerated dose (MTD) of B7H3-specific CAR (Arm A)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized to determine maximal tolerated dose

    28 days

  • To determine the maximum tolerated dose of bispecific B7H3xCD19 CAR (Arm B)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • To determine the feasibility of administration of pembrolizumab in combination with bispecific B7H3xCD19 CAR (Arm C)

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • To assess the dose limiting toxicities (DLTs) and describe the full toxicity profile for each study arm

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • To assess the feasibility of manufacturing B7H3 specific CARs from patient-derived lymphocytes

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

  • To assess the feasibility of manufacturing B7H3xCD19 bispecific CARs from patient-derived lymphocytes

    Type, frequency, severity, and duration of adverse events will be tabulated and summarized

    28 days

Secondary Outcomes (4)

  • Determine the duration of in vivo persistence of adoptively transferred T cells in the peripheral blood and compare engraftment between T cell products and treatment arms

    84 days

  • Determine the magnitude of in vivo persistence of adoptively transferred T cells in the peripheral blood and compare engraftment between T cell products

    84 days

  • Quantitate anti-tumor responses by measuring changes in tumor burden using disease-specific evaluations

    84 days

  • Describe the relative expansion and persistence of the CAR T cell product and retention of function for B7H3xCD19 bispecific CARs determined by maintenance of B cell aplasia (BCA) with and without pembrolizumab

    84 days

Other Outcomes (4)

  • Evaluate for the presence of B7H3 CAR T cells in tumor tissue and/or normal tissue if a tissue biopsy, tumor biopsy, or resection is clinically indicated post-treatment

    84 days

  • Evaluate B7H3 antigen expression in tumor tissue and/or normal tissue if a tissue biopsy, tumor biopsy, or resection is available

    84 days

  • Analyze blood, bone marrow, CSF, normal tissue, and/or tumor tissue for biomarkers of safety and/or anti-tumor activity

    84 days

  • +1 more other outcomes

Study Arms (3)

SCRI-CARB7H3(s)

EXPERIMENTAL

Autologous CD4+ and CD8+ T-cells genetically modified to express an B7H3-specific CAR

Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR

SCRI-CARB7H3(s)x19

EXPERIMENTAL

Autologous CD4+ and CD8+ T-cells genetically modified to a bispecific B7H3xCD19 CAR

Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

SCRI-CARB7H3(s)x19 plus pembrolizumab

EXPERIMENTAL

Autologous CD4+ and CD8+ T-cells genetically modified to express a bispecific B7H3xCD19 CAR given in combination with pembrolizumab

Biological: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGDrug: Pembrolizumab

Interventions

Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR

SCRI-CARB7H3(s)

SCRI-CARB7H3(s)x19 plus pembrolizumab

SCRI-CARB7H3(s)x19 plus pembrolizumab

Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG

SCRI-CARB7H3(s)x19SCRI-CARB7H3(s)x19 plus pembrolizumab

Eligibility Criteria

Age0 Years - 26 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Participants age ≤ 26 years at the time of consent for study participation; the first 2 participants enrolled and treated with CAR T cells in both Arms A and B will be ≥ 15 years. and ≤ 26 years at time of consent for study participation
  • Histologically diagnosed malignant, non-primary CNS solid tumor
  • Evidence of refractory or recurrent disease
  • Lansky or Karnofsky score ≥ 50
  • Life expectancy ≥ 8 weeks
  • Recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy and radiotherapy
  • If no apheresis product or usable T cell product is available, all chemotherapy has been discontinued ≥ 7 days prior to enrollment
  • If no apheresis or usable T cell product is available, all biologic therapy has been discontinued ≥ 7 days prior to enrollment
  • If no apheresis product or T cell product is available, all systemic corticosteroid therapy has been discontinued ≥ 7 days prior to enrollment (physiologic replacement dosing is allowed)
  • If no apheresis product or usable T cell product is available, at least 3 half-lives or 30 days (whichever is shorter) from time of last dose of anti-tumor directed antibody therapy (including checkpoint inhibitor) at time of enrollment
  • If no apheresis product or usable T cell product is available, at least 6 weeks post last dose of myeloablative therapy and autologous and/or allogeneic stem cell transplant, or non-myeloablative therapy and allogeneic stem cell transplant (all timed from stem cell infusion). Participants who receive autologous stem cell infusion following non-myeloablative therapy are eligible once all other eligibility requirements are met.
  • If no apheresis product or usable T cell product is available, participants who have received genetically modified cell therapy must be at least 30 days from most recent cell infusion prior to enrollment
  • If no apheresis product or usable T cell product is available, participants with neuroblastoma must be at least 12 weeks from I131 MIBG therapy.
  • Adequate organ function
  • Adequate laboratory values
  • +2 more criteria

You may not qualify if:

  • Presence of active malignancy other than primary malignant solid tumor diagnosis
  • Current relevant CNS pathology
  • Receiving external beam radiation therapy at time of enrollment
  • Presence of active GVHD, or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment
  • Participant is pregnant or breastfeeding
  • Participant has presence of active severe infection
  • Participant has presence of any condition that, in the option of an investigator, would prohibit the participant from undergoing treatment under this protocol
  • Participant has primary immunodeficiency syndrome
  • Unwilling or unable to provide consent/assent for participation in the study and 15 year follow up period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seattle Children's Hospital

Seattle, Washington, 98105, United States

Location

Related Publications (1)

  • Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, Wendler J, Pattabhi S, Seidel K, Brown C, Gustafson JA, Rawlings-Rhea SD, Cheeney SHE, Burleigh K, Gustafson HH, Orentas RJ, Vitanza NA, Gardner RA, Jensen MC, Park JR. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors. J Clin Oncol. 2024 Dec 10;42(35):4163-4172. doi: 10.1200/JCO.23.02229. Epub 2024 Sep 10.

MeSH Terms

Conditions

Neoplasms, Germ Cell and EmbryonalRetinoblastomaHepatoblastomaWilms TumorRhabdoid TumorCarcinomaOsteosarcomaSarcoma, EwingRhabdomyosarcomaSarcoma, SynovialSarcoma, Clear CellNeurofibrosarcomaDesmoplastic Small Round Cell TumorSarcomaNeuroblastomaMelanoma

Interventions

pembrolizumab

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueRetinal NeoplasmsEye NeoplasmsNeoplasms by SiteEye Diseases, HereditaryEye DiseasesRetinal DiseasesNeoplasms, Complex and MixedKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplastic Syndromes, HereditaryFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueMyosarcomaNeoplasms, Muscle TissueFibrosarcomaNeoplasms, Fibrous TissueNeurofibromaNerve Sheath NeoplasmsPeripheral Nervous System NeoplasmsNervous System NeoplasmsNervous System DiseasesPeripheral Nervous System DiseasesNeuromuscular DiseasesNeuroectodermal Tumors, Primitive, PeripheralNeuroectodermal Tumors, PrimitiveNeuroendocrine TumorsNevi and MelanomasSkin NeoplasmsSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Catherine Albert, MD

    Seattle Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Director, Seattle Children's Therapeutics

Study Record Dates

First Submitted

July 14, 2020

First Posted

July 23, 2020

Study Start

July 13, 2020

Primary Completion (Estimated)

December 1, 2040

Study Completion (Estimated)

December 1, 2040

Last Updated

April 28, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations